2024
Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial
Davar D, Morrison R, Dzutsev A, Karunamurthy A, Chauvin J, Amatore F, Deutsch J, Das Neves R, Rodrigues R, McCulloch J, Wang H, Hartman D, Badger J, Fernandes M, Bai Y, Sun J, Cole A, Aggarwal P, Fang J, Deitrick C, Bao R, Duvvuri U, Sridharan S, Kim S, A Choudry H, Holtzman M, Pingpank J, O'Toole J, DeBlasio R, Jin Y, Ding Q, Gao W, Groetsch C, Pagliano O, Rose A, Urban C, Singh J, Divarkar P, Mauro D, Bobilev D, Wooldridge J, Krieg A, Fury M, Whiteaker J, Zhao L, Paulovich A, Najjar Y, Luke J, Kirkwood J, Taube J, Park H, Trinchieri G, Zarour H. Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial. Cancer Cell 2024, 42: 1898-1918.e12. PMID: 39486411, PMCID: PMC11560503, DOI: 10.1016/j.ccell.2024.10.007.Peer-Reviewed Original ResearchConceptsPlasmacytoid dendritic cellsHigh-risk resected melanomaResected melanomaCD8<sup>+</sup> tumor-infiltrating lymphocytesAnti-PD-1 nivolumabAnti-tumor immune responseProspective phase II trialAnti-PD-1Associated with gene signaturesTumor-infiltrating lymphocytesPhase II trialResponse to therapySingle-arm studyAssociated with necrosisGut microbiotaClinical responseII trialPrimary endpointDendritic cellsTLR9 agonistsTumor microenvironmentT cellsMyeloid cellsPathological responseImmune activation
2023
Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-Risk Resected Melanoma
Goodman R, Lawless A, Woodford R, Fa’ak F, Tipirneni A, Patrinely J, Yeoh H, Rapisuwon S, Haydon A, Osman I, Mehnert J, Long G, Sullivan R, Carlino M, Menzies A, Johnson D. Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-Risk Resected Melanoma. JAMA Network Open 2023, 6: e2327145. PMID: 37535354, PMCID: PMC10401300, DOI: 10.1001/jamanetworkopen.2023.27145.Peer-Reviewed Original ResearchConceptsImmune-related adverse eventsAdjuvant anti-PD-1 therapyAnti-PD-1 therapyHigh-risk resected melanomaAnti-PD-1Follow-upAdverse eventsGrade 2Retrospective multicenter cohort studyLong-term follow-upCell death 1Relapse-free survivalMulticenter cohort studyLong-term outcomesExtended follow-upEvaluation follow-upCutaneous primaryDeath-1Resected melanomaStage IIIBSystemic steroidsMetastatic melanomaAdjuvant therapyTreatment cessationTherapy cessationLong-term outcomes of chronic immune-related adverse events from adjuvant anti-PD-1 therapy for high-risk resected melanoma.
Goodman R, Lawless A, Woodford R, Fa'ak F, Tipirneni A, Patrinely J, Yeoh H, Rapisuwon S, Haydon A, Osman I, Mehnert J, Long G, Sullivan R, Carlino M, Menzies A, Johnson D. Long-term outcomes of chronic immune-related adverse events from adjuvant anti-PD-1 therapy for high-risk resected melanoma. Journal Of Clinical Oncology 2023, 41: 9591-9591. DOI: 10.1200/jco.2023.41.16_suppl.9591.Peer-Reviewed Original ResearchAnti-PD1Long-term outcomesResected melanomaAdjuvant anti-PD-1 therapyFollow-upAnti-PD-1 therapyHigh-risk resected melanomaImmune-related adverse eventsStage III-IV melanomaLong-term follow-upAnti-PD-1Relapse-free survivalLong-term followLong-term survivorsAdrenal insufficiencyAdverse eventsTreated ptsDisease characteristicsHigh riskMelanomaProlonged monitoringLong-term effectsPatientsNO effectTreatment
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply